A new treatment has been made available to patients in the Republic of Ireland with chronic diabetic macular oedema (DMO).
Iluvien is an implant that is injected into the affected eye and lasts up to three years, providing a daily micro-dose of the corticosteroid FAc.
It is being made available in Ireland following an agreement between healthcare provider, Vhi, and manufacturer, Alimera Sciences.
Former President of the Irish College of Ophthalmologists, Marie Hickey Dwyer, said that the approval of Iluvien is exciting news for patients who are no longer responding to their first DMO treatment.
“Diabetes remains the most serious cause of severe vision loss in people of working age in Ireland, and DMO is the cause in around 10% of those cases,” she explained.
“The Iluvien implant could mean the difference between a patient having increasingly deteriorating sight, and being able to drive again. I look forward to having it as an option for my patients,” Ms Dwyer added.